| Tyra Biosciences to Participate at Upcoming Investor Conferences |
CARLSBAD, Calif. , May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: Bank of America Global Healthcare Conference, May 13-15, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Tuesday, May 13, 2025, at 5:15 PM PT Location: Las Vegas, NV Jefferies Global Healthcare Conference, June 3-5, 2025 Format: One-on-one investor meetings Location: New York, NY UBS Biotech 1x1 Symposium, June 24, 2025 Format: One-on-one investor meetings Location: New York, NY A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website. |
prnewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights |
- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular carcinoma (HCC) - - Cash, cash equivalents, and marketable securities of $318.9 million at Q1 2025; runway through at least 2027 - CARLSBAD, Calif. , May 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights |
- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC), BEACH301 for pediatric achondroplasia (ACH) and SURF301 for metastatic urothelial cancer (mUC) - - Cash, cash equivalents, and marketable securities of $341.4 million at YE 2024; runway through at least 2027 - CARLSBAD, Calif. , March 27, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress. |
prnewswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences to Present at Upcoming Investor Conferences |
CARLSBAD, Calif. , Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, February 12, 2025, at 2:00 PM ET Location: Virtual TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Monday, March 3, 2025, at 9:50 AM ET Location: Boston Jefferies Biotech on the Beach Summit, March 11-12, 2025 Format: One-on-one investor meetings Location: Miami Barclays 27th Annual Global Healthcare Conference, March 11-13, 2025 Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Wednesday, March 12, 2025, at 8:30 AM ET Location: Miami A live and archived webcast of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website. |
prnewswire.com |
2025-02-11 18:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium |
CARLSBAD, Calif. , Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts were accepted for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), taking place January 23-25, 2025, in San Francisco, CA. |
prnewswire.com |
2025-01-22 10:00:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) |
-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif. |
prnewswire.com |
2025-01-10 10:00:00 |
Czytaj oryginał (ang.) |
| Post-Election Insider Buying in These 6 Stocks Is Huge |
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases. |
247wallst.com |
2024-11-17 10:15:11 |
Czytaj oryginał (ang.) |
| Tyra Biosciences to Present at Upcoming Investor Conferences |
CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences: Jefferies London Healthcare Conference, November 19-21st, 2024: Todd Harris, CEO of TYRA, will participate in a fireside chat on Tuesday, November 19th, at 2:00 pm GMT. |
prnewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights |
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as Chief Medical Officer - - Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended September 30, 2024, and highlighted recent corporate progress. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) |
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 for children with achondroplasia (BEACH301). |
prnewswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? |
On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study. |
benzinga.com |
2024-10-25 15:34:53 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) |
- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif. , Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study. |
prnewswire.com |
2024-10-24 22:21:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET |
CARLSBAD, Calif. , Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). |
prnewswire.com |
2024-10-23 20:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point |
Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. |
seekingalpha.com |
2024-10-21 11:55:21 |
Czytaj oryginał (ang.) |
| BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug |
BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines. |
benzinga.com |
2024-10-18 18:34:54 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) |
-TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 - CARLSBAD, Calif. , Oct. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the selection of three abstracts for presentation, including a late-breaking oral presentation, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, in Barcelona, Spain. |
prnewswire.com |
2024-10-11 12:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation |
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-12 15:00:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference |
CARLSBAD, Calif. , Sept. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today its participation at the 2024 Cantor Global Healthcare Conference. |
prnewswire.com |
2024-09-11 20:05:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation |
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-11 08:00:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer |
-Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease- CARLSBAD, Calif. , Sept. 10, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Doug Warner, M.D. |
prnewswire.com |
2024-09-10 20:05:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Has Launched An Inquiry Into Tyra Biosciences Inc For Securities Law Violations And Investors Are Urged To Contribute |
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-10 15:00:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders To Participate |
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-09 15:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet |
The consensus price target hints at a 27.9% upside potential for Tyra Biosciences (TYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-09-09 14:56:11 |
Czytaj oryginał (ang.) |
| Fraudulent Practices May Have Been Committed By Tyra Biosciences Inc And Affected Investors Are Urged To Reach Out To The Schall Law Firm |
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-07 15:00:00 |
Czytaj oryginał (ang.) |
| Investors Are Invited By The Schall Law Firm To Partake In An Inquiry In Tyra Biosciences, Inc's Possible Violations Of Securities Regulations |
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-06 15:00:00 |
Czytaj oryginał (ang.) |
| Tyra Biosciences, Inc. Is Being Looked Into For Acting Wrongfully And The Schall Law Firm Has Launched An Investigation That Shareholders Can Join |
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or "the Company") (NASDAQ:TYRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-09-05 15:00:00 |
Czytaj oryginał (ang.) |